Abstract | OBJECTIVE: METHOD: RESULTS: CONCLUSIONS: Recently, the sigma-1 receptor agonist fluvoxamine has been considered beneficial for various neuropsychiatric disorders. However, data about the effects of fluvoxamine on hyperkinetic movement disorders are limited. In this report, we attempted to demonstrate the beneficial effects of fluvoxamine on TD, and we suggest that the mechanism of action might be due to sigma-1 agonism. Further detailed, double-blind studies should clarify the potential use of fluvoxamine in the treatment of hyperkinetic movement disorders.
|
Authors | Yakup Albayrak, Kenji Hashimoto |
Journal | The primary care companion for CNS disorders
(Prim Care Companion CNS Disord)
Vol. 14
Issue 6
( 2012)
ISSN: 2155-7772 [Print] United States |
PMID | 23585988
(Publication Type: Journal Article)
|